# Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

> **NCT01748747** · EARLY_PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 30 (actual)

## Conditions studied

- Recurrent Melanoma
- Stage IIA Melanoma
- Stage IIB Melanoma
- Stage IIC Melanoma
- Stage IIIA Melanoma
- Stage IIIB Melanoma
- Stage IIIC Melanoma
- Stage IV Melanoma

## Interventions

- **DRUG:** Montanide ISA 51 VG
- **BIOLOGICAL:** MART-1 antigen
- **OTHER:** laboratory biomarker analysis
- **BIOLOGICAL:** Gag:267-274 peptide vaccine
- **DRUG:** resiquimod

## Key facts

- **NCT ID:** NCT01748747
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2014-12-14
- **Final completion:** 2017-03-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01748747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01748747, "Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01748747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*